Uso de inibidores de SGLT2 no tratamento da insuficiência cardíaca: impacto na mortalidade e hospitalizações

Abstract

This study aims to use SGLT2 inhibitors in the treatment of heart failure, focusing on their impact on mortality and hospitalizations. The research was conducted using the PubMed index with the terms "SGLT2 inhibitors AND heart failure with reduced ejection fraction AND mortality reduction." The results indicate that this serious condition requires continuous monitoring involving various measures, such as sodium-glucose cotransporter type 2 (SGLT2) inhibitors, which demonstrate a 26% reduction in cardiovascular risk for patients using Dapagliflozin. Additionally, although recommended as standard treatment for patients and with evidence showing significant reductions in mortality and hospitalizations due to heart failure, the mechanisms of action of SGLT2 inhibitors are not fully understood. Thus, there is a need for more detailed and specific analysis of these mechanisms to better understand the clinical effects associated with them. Despite being primarily developed for the treatment of Type 2 Diabetes Mellitus, a reduction in adverse clinical outcomes has been observed in patients with heart failure with reduced ejection fraction (HFrEF).